Vivos Therapeutics, Inc. (NASDAQ: VVOS ) Q4 2024 Earnings Conference Call: Key Insights
On March 31, 2025, at 5:00 PM ET, Vivos Therapeutics, Inc. (Vivos) held its Full Year 2024 Earnings Conference Call. The call was attended by Bradford Amman, CFO, Treasurer & Secretary, and Kirk Huntsman, Co-Founder, Chairman & CEO of Vivos. The conference call was also participated by Guyn Kim from Water Tower Research, Scott Henry from Alliance Global Partners, and Lucas Ward from Ascendiant Capital Markets, among others.
Company Overview
Vivos Therapeutics is a medical technology company that focuses on developing and commercializing innovative solutions for obstructive sleep apnea (OSA). OSA is a chronic condition characterized by repeated obstructions in the upper airway during sleep, leading to sleep fragmentation and daytime sleepiness.
Financial Highlights
During the call, Vivos’ management provided an update on the company’s financial performance for the full year 2024. The company reported a revenue of $25.5 million, a significant increase from the $18.7 million reported in the same period last year. The net loss for the year was $12.8 million, compared to a net loss of $17.3 million in 2023.
The management attributed the revenue growth to the increasing adoption of the company’s proprietary SnoreRx Mandibular Advancement Device (MAD) and the expansion of its international distribution network.
Product Updates
The management also provided updates on the company’s product pipeline. They announced the successful completion of the clinical trial for their new product, the VivosID, a custom-fit oral appliance designed for the treatment of obstructive sleep apnea. The company plans to submit the data from the trial to the Food and Drug Administration (FDA) for approval in the second quarter of 2025.
Market Opportunity
During the call, the management discussed the significant market opportunity for their products. They estimated that there are approximately 100 million adults in the United States and Europe suffering from obstructive sleep apnea, and only a small fraction of them are currently being treated. The management believes that their proprietary technology and expanding distribution network position them well to capture a significant share of this market.
Impact on Individuals
For individuals suffering from obstructive sleep apnea, the development of new and effective treatments can have a significant positive impact on their quality of life. OSA can lead to daytime sleepiness, fatigue, and other health complications. Effective treatments, such as the ones offered by Vivos, can help alleviate these symptoms and improve overall health and well-being.
Impact on the World
Obstructive sleep apnea is a chronic condition that affects millions of people worldwide. The development of new and effective treatments, such as those offered by Vivos, can have a significant positive impact on public health. By improving the quality of life for individuals suffering from OSA, these treatments can lead to increased productivity, reduced healthcare costs, and improved overall well-being.
Conclusion
In conclusion, Vivos Therapeutics’ Full Year 2024 Earnings Conference Call provided valuable insights into the company’s financial performance, product pipeline, and market opportunity. The company’s revenue growth and expanding distribution network are promising signs of a successful business model. The successful completion of clinical trials for new products, such as the VivosID, further underscores the company’s commitment to innovation and improving the lives of individuals suffering from obstructive sleep apnea.
For individuals, the development of new and effective treatments for obstructive sleep apnea can have a significant positive impact on their quality of life. For the world, the continued advancement of these treatments can lead to improved public health, increased productivity, and reduced healthcare costs.
- Vivos Therapeutics reported a revenue of $25.5 million for full year 2024, a significant increase from $18.7 million in 2023.
- The company announced the successful completion of clinical trials for their new product, the VivosID, a custom-fit oral appliance designed for the treatment of obstructive sleep apnea.
- Management estimated that there are approximately 100 million adults in the US and Europe suffering from obstructive sleep apnea, and only a small fraction of them are currently being treated.
- The development of new and effective treatments for obstructive sleep apnea can lead to improved public health, increased productivity, and reduced healthcare costs.
